reason report
higher pt
bottom line yesterday market close ew report
except strong quarter -- adjust sale
includ adjust stock inventori germani
y/i ex fx come ahead us
ahead consensu ew beat predominantli broad-bas across
busi -- notabl -- thv transcathet heart
valv ww thv sale came y/i vs estim
street manag cite strong
adopt momentum stabl sell price primari driver
notabl commentari call also particularli bullish
manag rais sale ep guidanc toward high end
previous state rang midpoint
lower tax contribut half ep
increas higher sale contribut half think clearli
encourag sign manag seem increasingli confid
recent adopt momentum sustain ew share like move
higher print deservedli one quarter
necessarili make trend acknowledg clearli
quarter offer strongli posit signal perhap reach
inflect point see steadier
consist intermedi risk ramp seeing/wer
expect street expect seem come
reason level out-year project low-
mid-teen market growth remain sidelin
given expect like move higher print
continu look sign intermedi risk ramp
inflect otherwis catalyst-heavi year low
risk data come
reiter mp pt price target --
-- appli price-to-earnings multipl now-high ep
estim assum stabl multipl current level
premium large-cap med-tech group believ warrant
given ew top-tier growth profil heavi exposur high-growth
outlook estim move higher
sale estim move y/i y/
-- nearli prior higher thv sale realli drive
lion share move estim ep estim
previous reflect higher revenu
growth favor fx impact lower tax rate
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
ep
compani inform leerink partner llc research
revenu mm non-gaap dilut adjust ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate edward lifesci nyse ew share market perform
price target edward current market leader tavr transcathet aortic
valv replac market intern continu believ tavr
repres one excit new med-tech market high-teen higher
project market compound-annual-growth-rate time-frame base estim sens
ramp less sick patient popul current intermedi risk potenti
low risk beyond might occur slower pace already-elev investor
expect continu believ intermedi risk indic repres massiv
increment market opportun estim intermedi risk doubl
address patient popul also believ ramp patient may slower
saw inoper high risk given linger question around tavr
durabl longer term need seemingli intens market develop effort
drive referr particularli younger less sick portion intermedi risk patient
popul potenti increas surgeon pushback less sick patient popul
heart member ramp effort preserv surgic busi
ultim believ global tavr market exceed line ew
guidanc new indic come on-line low risk eventu asymptomat
near-to-medium term ew still beat rais stori base earli read
intermedi risk adopt ramp think beat next month may
smaller tougher come last two year particularli light
competit launch addit steadier intermedi risk ramp vs step function chang
growth street seem expect share current trade earn
becom increasingli difficult argu meaning multipl expans leav us
upsid current level base estim
price target appli price-to-earnings multipl ep estim
pt assum ew maintain current multipl ep also think ew
market-lead posit highli under-penetrated total address market justifi
compani premium valuat rel rest large-cap med-tech group
risk includ inflect point intermedi risk adopt ramp neg competit
clinic data and/or competit launch delay faster-than-expect low risk
asymptomat trial ramp earlier-than-expect cardiaq feasibl trial re-start
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
incom continu oper
sg sale
 sale
oper expens sale
compani report leerink partner estim
dollar million except per share data
good sold
research develop expens
incom continu oper
revenu
consensu incom statement item includ contributor factset
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report leerink partner estim factset visibl alpha
dollar million except per share data
good sold
research develop expens
incom continu oper
revenu
consensu incom statement item includ contributor factset
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report leerink partner estim factset visibl alpha
sg sale sale
high end
higher end
midpoint
tmtt
tmtt
midpoint
high end
high end
high end
high end
